These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22052606)

  • 1. The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens.
    Chen YH; Ko WC; Hsueh PR
    Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):1699-704. PubMed ID: 22052606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance.
    Miller LG; Tang AW
    Mayo Clin Proc; 2004 Aug; 79(8):1048-53; quiz 1053-4. PubMed ID: 15301333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections.
    Carson C; Naber KG
    Drugs; 2004; 64(12):1359-73. PubMed ID: 15200349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative
    Afriyie DK; Adu LB; Dzradosi M; Amponsah SK; Ohene-Manu P; Manu-Ofei F
    Pan Afr Med J; 2018; 30():194. PubMed ID: 30455823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region.
    Hsueh PR; Hoban DJ; Carmeli Y; Chen SY; Desikan S; Alejandria M; Ko WC; Binh TQ
    J Infect; 2011 Aug; 63(2):114-23. PubMed ID: 21669223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections.
    Talan DA; Naber KG; Palou J; Elkharrat D
    Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S54-66. PubMed ID: 15037329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effectiveness of beta-lactams versus fluoroquinolones as empirical therapy in patients with diabetes mellitus hospitalized for urinary tract infections: A retrospective cohort study.
    Tang YH; Lu PL; Huang HY; Lin YC
    PLoS One; 2022; 17(3):e0266416. PubMed ID: 35358291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option.
    Blondeau JM
    Drugs; 2004; 64(6):611-28. PubMed ID: 15018591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoroquinolone resistant bacterial isolates from the urinary tract among patients attending hospitals in Bushenyi District, Uganda.
    Odoki M; Aliero AA; Tibyangye J; Maniga JN; Eilu E; Ntulume I; Wampande E; Kato CD; Agwu E; Bazira J
    Pan Afr Med J; 2020; 36():60. PubMed ID: 32733630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolones in the treatment of acute uncomplicated urinary tract infections in adult women.
    Garrison J; Hooton TM
    Expert Opin Pharmacother; 2001 Aug; 2(8):1227-37. PubMed ID: 11584990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expanding role of fluoroquinolones.
    Schaeffer AJ
    Am J Med; 2002 Jul; 113 Suppl 1A():45S-54S. PubMed ID: 12113871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating outcomes associated with revised fluoroquinolone breakpoints for Enterobacterales urinary tract infections: A retrospective cohort study.
    Benavides TM; Aden JK; Giancola SE
    Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):741-749. PubMed ID: 35224677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance Patterns of Escherichia coli in Women with Uncomplicated Urinary Tract Infection Do Not Correlate with Emergency Department Antibiogram.
    Hines MC; Al-Salamah T; Heil EL; Mallemat H; Witting MD; Johnson JK; Winters ME; Hayes BD
    J Emerg Med; 2015 Dec; 49(6):998-1003. PubMed ID: 26281821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoroquinolone-resistant uncomplicated urinary tract infections, Chinese herbal medicine may provide help.
    Tong Y; Jing Y; Zhao D; Zhang L; Zeng S
    Afr J Tradit Complement Altern Med; 2011; 8(5 Suppl):108-14. PubMed ID: 22754063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes.
    Labreche MJ; Frei CR
    Am J Health Syst Pharm; 2012 Nov; 69(21):1863-70. PubMed ID: 23111670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis.
    Bientinesi R; Murri R; Sacco E
    Expert Opin Pharmacother; 2020 Apr; 21(6):637-644. PubMed ID: 32004097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and risk factors for trimethoprim-sulfamethoxazole-resistant Escherichia coli among women with acute uncomplicated urinary tract infection in a developing country.
    Gangcuangco LM; Alejandria M; Henson KE; Alfaraz L; Ata RM; Lopez M; Saniel M
    Int J Infect Dis; 2015 May; 34():55-60. PubMed ID: 25748571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs for Gram-positive uropathogens.
    Wagenlehner FM; Naber KG
    Int J Antimicrob Agents; 2004 Sep; 24 Suppl 1():S39-43. PubMed ID: 15364305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.